Guangzhou Baiyunshan Pharmaceutical Holdings Company (HK:0874) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Guangzhou Baiyunshan Pharmaceutical Holdings Company’s subsidiary, Tianxin Pharmaceutical, has received approval from the National Medical Products Administration for its generic drug, Cefoperazone Sodium for Injection (0.5g, 1.0g), which has passed the quality and therapeutic consistency evaluation. This achievement assures the drug’s quality and effectiveness, aligning with industry standards. The company’s board and directors have confirmed the authenticity and completeness of this announcement, assuming legal responsibility for its truthfulness.
For further insights into HK:0874 stock, check out TipRanks’ Stock Analysis page.